Russell Frank Company’s PTC Therapeutics PTCT Stock Holding History

Russell Frank Company’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$194K	Sell	30,145 -58,589	-66%	-$1.02M	﹤0.01%	2678
2015 Q4	$2.9M	Sell	88,734 -133,043	-60%	-$3.92M	0.01%	1605
2015 Q3	$5.92M	Sell	221,777 -15,091	-6%	-$645K	0.01%	1177
2015 Q2	$11.4M	Buy	236,868 +216,424	+1,059%	+$12.6M	0.02%	900
2015 Q1	$1.24M	Sell	20,444 -30,043	-60%	-$1.83M	﹤0.01%	2032
2014 Q4	$2.61M	Sell	50,487 -2,772	-5%	-$122K	﹤0.01%	1635
2014 Q3	$2.34M	Sell	53,259 -29,933	-36%	-$936K	﹤0.01%	1661
2014 Q2	$2.17M	Buy	+83,192	New	+$1.78M	﹤0.01%	1711
2013 Q4	–	Sell	-23,900	Closed	-$513K	–	2994
2013 Q3	$513K	Buy	+23,900	New	+$415K	﹤0.01%	2478

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Russell Frank Company's PTCT Position: Q1 2016 in Review

Russell Frank Company reduced its PTC Therapeutics (PTCT) stake by 66% in Q1 2016, selling an estimated $1.02M and leaving 30,145 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #2678.

Russell Frank Company first reported a position in PTCT in Q3 2013 and has held it in 9 quarters since. The position peaked at $11.4M in Q2 2015. 119 funds tracked by Wall St. Rank hold PTCT as of Q1 2016.

Russell Frank Company held 30,145 shares of PTC Therapeutics worth $194K as of Q1 2016.
Russell Frank Company sold 58,589 PTC Therapeutics shares in Q1 2016, an estimated $1.02M.
PTC Therapeutics made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2678 holding.
Russell Frank Company first reported a position in PTC Therapeutics in Q3 2013 and has held it in 9 quarters since.
Russell Frank Company's PTC Therapeutics position peaked at $11.4M in Q2 2015.
119 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.